Moderna, Inc. (MRNA): Total Liabilities
$3.69B
As of 2025-12-31
$4.20B
As of 2026-06-30
-18.2%
3-year compound annual growth
-5.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.69B | +13.8% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $3.24B | -29.1% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $4.57B | -32.1% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $6.74B | -36.0% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $10.52B | +120.4% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $4.78B | n/m | 2022-02-25, Balance as of period end |
| 2019-12-31 | $414.61M | -4.0% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $431.91M | -5.9% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $459.19M | n/a | 2019-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.69B | +13.8% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $683.10M | -2.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
Compare MRNA, EXEL, HALO, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗